Thelansis

 Non-small cell lung cancer (NSCLC) is the predominant variant of lung cancer, comprising most cases. About 18% of these cases pertain to early-stage NSCLC, typically necessitating a multifaceted therapeutic approach to a potential cure. The origins of NSCLC can classified into two distinct categories: factors that could have been avoided and those that were unavoidable. Among the most renowned avoidable risk factors for NSCLC is the inhalation of tobacco, but other contributors encompass alcohol consumption, exposure to secondhand smoke, contact with hazardous substances like asbestos, radon, arsenic, chromium, and nickel, as well as exposure to ionizing radiation and polycyclic aromatic hydrocarbons. Radiation therapy in treating other malignancies, such as breast cancer and Hodgkin lymphoma can also induce primary lung cancer. The suspicion of NSCLC diagnosis typically arises when a patient presents with intrathoracic symptoms and is subsequently found to have a pulmonary nodule...

  Non–small cell lung cancer (NSCLC) is the most common form of lung cancer. Early-stage NSCLC accounts for approximately 18% of the cases. Most patients are treated with curative intent and often require multimodality therapy. The 5-year overall survival (OS) ranges from 50% for stage IA disease to 15% for stage IIIA NSCLC. Several clinical trials have demonstrated improved survival with postoperative chemotherapy in selected patients who undergo complete surgical resection. Available evidence supports the use of adjuvant chemotherapy for stage II and stages IIIA but not for stage IA NSCLC. The standard of care for patients with stage I and II and IIIA, non-small-cell lung cancer (NSCLC), is surgical resection. Following resection, patients may be offered adjuvant systemic therapy. HER2 mutations and HER2 amplifications have been reported in approximately 2% to 3% and 2% to 5% of lung adenocarcinomas, respectively. Thelansis’s “Non–Small Cell Lung Cancer (NSCLC) Ma...